Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
96 participants
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Drugs for experimental group
GanMaoKangNing Granules， blunted by boiled water , 3 times a day, 2 bags each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.); Analogous Oseltamivir Phosphate Capsules,take oral,2 times a day,1 capsule each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.).
GanMaoKangNing Granules
3 times a day, 2 bags each time.
Analogous Oseltamivir Phosphate Capsules
2 times a day,1 capsule each time.
Drugs for control group
Oseltamivir Phosphate Capsules ,take oral,2 times a day,1 capsule each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.); Analogous GanMaoKangNing Granules, blunted by boiled water , 3 times a day, 2 bags each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.).
Oseltamivir Phosphate Capsules
2 times a day,1 capsule each time.
Analogous GanMaoKangNing Granules
3 times a day, 2 bags each time.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GanMaoKangNing Granules
3 times a day, 2 bags each time.
Analogous Oseltamivir Phosphate Capsules
2 times a day,1 capsule each time.
Oseltamivir Phosphate Capsules
2 times a day,1 capsule each time.
Analogous GanMaoKangNing Granules
3 times a day, 2 bags each time.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male and female patients aged between 18 and 65 years old , there is no limit on the gender;
* In line with the diagnostic criteria for pandemic influenza;
* Duration less than 48 (Duration is defined as the time from onset to test drugs for the first time before, the onset time pointed out that now the axillary temperature 38.0 ℃, headache, muscle or joint pain, chills, fatigue, cough, sore throat and a stuffy nose eight any flu symptoms and signs in time);
* The axillary temperature is 38.0 ℃ or higher;
* Nose and throat swabs rapid virus antigen test result is positive.
Exclusion Criteria
* With the following any severe risk factors:
A. With chronic respiratory diseases such as bronchial asthma, chronic obstructive pulmonary disease (copd), etc.
B. with chronic diseases of the cardiovascular system, such as congestive heart failure, high blood pressure.
C. with chronic metabolic and endocrine system diseases, such as poorly controlled diabetes (HbA1c 7.0% or higher).
D. with chronic kidney disease, chronic liver disease, blood system diseases, neurological and neuromuscular diseases (such as epilepsy, cognitive impairment, etc.).
E. A weakened immune system, such as long-term use of immunosuppressive agents, HIV infection or tumor.
F. Under the age of 19, long-term aspirin use. G. The obese (BMI BMI \> 30).
* With influenza complications, such as secondary bacterial pneumonia and other pathogenic bacteria and other viral pneumonia caused by pneumonia.
* A history of peptic ulcer disease or gastrointestinal bleeding.
* Into the group received within 48 h before flu antiviral treatment.
* Into the group of 12 months before been vaccinated against the flu.
* Into the group used within 2 weeks before the monoamine oxidase inhibitors.
* Blood leukocyte count \> 10.0 x 109 / L, neutrophils ratio \> 80%, or the need for systemic antibiotic therapy.
* For GanMaoKangNing Granules, Oseltamivir Phosphate Capsules, Acetaminophen Tablets, Dextromethorphan Hydrobromide Capsule, GanMaoKangNing Granules simulation agent or Oseltamivir Phosphate Capsules simulation agent composition of allergy, or allergic constitution.
* Aminotransferase (AST/SGOT) or alanine aminotransferase (ALT/SGPT) ≥ 1.5 x Upper Limit Normal (ULN)， Scr \> Upper Limit Normal (ULN).
* Doubt or does have a history of alcohol or drug abuse.
* Pregnancy (defined as the pregnancy test positive), nursing mothers, or past in family planning.
* For nearly three months participated in other clinical trials of patients.
* Researchers think not appropriate to participate in this clinical subjects.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dalian Zhen-Ao Bio-Tech Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jing Wang Jing Wang, Dr.
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
WHO. Influenza（Seasonal）\[EB/OL\].\[2015-12-31\]
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DalianZhen-Ao
Identifier Type: -
Identifier Source: org_study_id